Cyclooxygenase Inhibitors and Cardiovascular Risk—Reply

David Henry*, Patricia McGettigan

*Corresponding author for this work

Research output: Contribution to journalLetterResearchpeer-review

1 Citation (Scopus)


In Reply: Dr Andersohn and colleagues suggest that the highest risks of cardiovascular events with celecoxib are seen in European study populations, where the CYP2C9*3 allele associated with slow metabolism of celecoxib (and by implication an increased risk of thrombosis) may occur with a frequency of as much as 16%. This is an interesting suggestion, but we can speculate that it may not be the most likely explanation for the heterogeneity observed in the study results.
Original languageEnglish
Pages (from-to)587-588
Number of pages2
JournalJournal of the American Medical Association
Issue number6
Publication statusPublished - 14 Feb 2007
Externally publishedYes


Dive into the research topics of 'Cyclooxygenase Inhibitors and Cardiovascular Risk—Reply'. Together they form a unique fingerprint.

Cite this